First National Bank of Omaha Takes Position in Pfizer Inc. $PFE

First National Bank of Omaha acquired a new position in shares of Pfizer Inc. (NYSE:PFE) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 40,148 shares of the biopharmaceutical company’s stock, valued at approximately $1,023,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Curio Wealth LLC lifted its position in Pfizer by 36,600.0% during the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 1,098 shares in the last quarter. Grey Fox Wealth Advisors LLC purchased a new position in shares of Pfizer in the 3rd quarter valued at $29,000. Howard Hughes Medical Institute purchased a new stake in Pfizer during the 2nd quarter worth $30,000. Darwin Wealth Management LLC acquired a new stake in Pfizer in the 2nd quarter valued at $32,000. Finally, Evelyn Partners Asset Management Ltd purchased a new position in Pfizer in the second quarter valued at about $33,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of Pfizer stock opened at $27.41 on Thursday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.94. The firm’s 50-day simple moving average is $25.91 and its 200-day simple moving average is $25.28. The firm has a market cap of $155.82 billion, a PE ratio of 20.15 and a beta of 0.47.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The firm had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. During the same period in the previous year, the company earned $0.63 earnings per share. Pfizer’s quarterly revenue was down 1.2% on a year-over-year basis. Equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a yield of 6.3%. Pfizer’s dividend payout ratio (DPR) is 126.47%.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on PFE shares. Morgan Stanley dropped their target price on Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a report on Friday, December 12th. Bank of America reduced their target price on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research report on Monday, December 15th. Citigroup assumed coverage on shares of Pfizer in a report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price target for the company. Daiwa Securities Group lowered shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price objective on the stock. in a report on Thursday, February 12th. Finally, HSBC restated a “buy” rating and set a $29.00 target price on shares of Pfizer in a research note on Wednesday, December 10th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, thirteen have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $28.00.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.